Sunitinib Sutent
Used in colorectal cancer outside its approved indication. It appears in 9 clinical trials.
What it is
Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor that has been evaluated for colorectal cancer treatment, particularly in combination with standard chemotherapy regimens like FOLFIRI and FOLFOX. While primarily approved for renal cell carcinoma and gastrointestinal stromal tumors, sunitinib has shown activity against metastatic colorectal cancer by inhibiting angiogenesis and tumor growth. In colorectal cancer, it has been tested as both first-line and subsequent therapy, often in combination with fluoropyrimidine-based chemotherapy regimens.
How it works
Sunitinib inhibits multiple receptor tyrosine kinases including VEGFR-1, VEGFR-2, VEGFR-3, PDGFR- , PDGFR- , KIT, FLT3, CSF-1R, and RET. By blocking these pathways, particularly the VEGF receptors, sunitinib disrupts tumor angiogenesis and inhibits tumor cell proliferation and survival.
Molecular targets
Common side effects
Not all are listed, and everyone experiences them differently. If you notice any, tell your care team.
Trials with this drug
Guides that may help
Written for patients and families, in plain language.